Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

Discover the emerging science in atopic dermatitis (AD) from experts in the field

DUPIXENT Webinars & Symposiums 2021

ADVANCE 2021 WEBINAR

Discussions on clinical trial data and real-world experience supporting the use of DUPIXENT in children (6–11) and the psychological burden of AD and how to manage it.

BAD SYMPOSIUM 2021

“Experience from two UK centres and implications for treatment in the COVID-19 era”, presented by Professor Carsten Flohr, Dr Hamish Hunter and Dr Richard Woolf.

DUPIXENT Webinars & Symposiums 2020

BAD SYMPOSIUM 2020

See what was presented by Dermatologists at the Sanofi-sponsored BAD 2020 symposium, “Clinical experience of DUPIXENT for adults and adolescents with moderate-to-severe AD”.

PROFESSOR ALAN IRVINE

The clinical implications of Type 2 inflammation in AD, presented at the Clinical Dermatology Update 2020.

ADvance 2019

DUPIXENT in adolescents with moderate-to-severe AD

DR BEN WALKER

Discusses the policies that govern access to dupilumab for adolescents with moderate-to-severe AD in the UK.

SEVERAL EXPERTS

Discuss how do you define a ‘moderate’ patient – adult or adolescent?

DR TESS MCPHERSON

Discusses the opportunities and challenges of managing adolescent patients with AD.

TEENA MACKENZIE

Discusses the role of a Dermatology nurse in managing and supporting adolescents with moderate-to-severe AD and their carers.

DR TIM CLAYTON

Discusses the pathophysiology of AD and the treatment options for adolescents with moderate-to-severe disease.

PROFESSOR MICHAEL CORK

Discusses the role of DUPIXENT in the treatment of adolescents with moderate-to-severe AD.

ADvance 2018

DUPIXENT in adults with moderate-to-severe AD

DR ANTHONY BEWLEY

Discusses AD and the mind.

PROFESSOR MICHAEL CORK

Discusses the unmet need in AD.

PROFESSOR ALAN IRVINE

Discusses the pathophysiology of AD and key DUPXIENT trial data.

AD, atopic dermatitis; BAD, British Association of Dermatologists.

References

  1. DUPIXENT Summary of Product Characteristics. September 2021.